Condensed Consolidated Statements of Changes in Shareholders' Deficit - USD ($) |
Common Stock [Member]
Aspire Biopharma Inc [Member]
|
Common Stock [Member] |
Preferred Stock [Member]
Aspire Biopharma Inc [Member]
Series A Preferred Stock [Member]
|
Preferred Stock [Member] |
Additional Paid-in Capital [Member]
Aspire Biopharma Inc [Member]
|
Additional Paid-in Capital [Member] |
Retained Earnings [Member]
Aspire Biopharma Inc [Member]
|
Retained Earnings [Member] |
Aspire Biopharma Inc [Member] |
Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance at Dec. 30, 2023 | $ 22,000 | $ 957,500 | $ (1,467,361) | $ (487,861) | ||||||
| Balance, shares at Dec. 30, 2023 | 440,000,000 | |||||||||
| Retroactive application of recapitalization, shares | (412,418,421) | |||||||||
| Balance at Dec. 31, 2023 | $ 22,000 | $ 2,758 | $ 957,500 | 976,742 | $ (1,467,361) | (1,467,361) | $ (487,861) | (487,861) | ||
| Balance, shares at Dec. 31, 2023 | 440,000,000 | 27,581,579 | ||||||||
| Retroactive application of recapitalization | $ (19,242) | 19,242 | ||||||||
| Issuance of common stock | $ 2 | 229,082 | 229,084 | |||||||
| Issuance of common stock, shares | 17,950 | |||||||||
| Net (loss) gain for the period | (230,970) | (230,970) | ||||||||
| Balance at Mar. 31, 2024 | $ 2,760 | 1,205,824 | (1,698,331) | (489,747) | ||||||
| Balance, shares at Mar. 31, 2024 | 27,599,529 | |||||||||
| Balance at Dec. 31, 2023 | $ 22,000 | $ 2,758 | 957,500 | 976,742 | (1,467,361) | (1,467,361) | (487,861) | (487,861) | ||
| Balance, shares at Dec. 31, 2023 | 440,000,000 | 27,581,579 | ||||||||
| Net (loss) gain for the period | (544,162) | |||||||||
| Balance at Sep. 30, 2024 | $ 2,760 | 1,234,385 | (2,011,523) | (774,378) | ||||||
| Balance, shares at Sep. 30, 2024 | 27,601,767 | |||||||||
| Balance at Dec. 31, 2023 | $ 22,000 | $ 2,758 | 957,500 | 976,742 | (1,467,361) | (1,467,361) | (487,861) | (487,861) | ||
| Balance, shares at Dec. 31, 2023 | 440,000,000 | 27,581,579 | ||||||||
| Issuance of common stock | ||||||||||
| Issuance of common stock, shares | ||||||||||
| Issuance of shares under working capital loans and non redemption agreements | $ 32 | 257,613 | 257,645 | |||||||
| Issuance of shares under working capital loans and non redemption agreements, shares | 322,059 | |||||||||
| Net (loss) gain for the period | (1,309,872) | (1,309,872) | ||||||||
| Balance at Dec. 31, 2024 | $ 22,000 | $ 2,760 | $ 32 | 1,215,113 | 1,234,385 | (2,777,233) | (2,777,233) | (1,540,088) | (1,540,088) | |
| Balance, shares at Dec. 31, 2024 | 440,000,000 | 27,601,767 | 322,059 | |||||||
| Balance at Mar. 31, 2024 | $ 2,760 | 1,205,824 | (1,698,331) | (489,747) | ||||||
| Balance, shares at Mar. 31, 2024 | 27,599,529 | |||||||||
| Issuance of common stock | 28,561 | 28,561 | ||||||||
| Issuance of common stock, shares | 2,238 | |||||||||
| Net (loss) gain for the period | (96,923) | (96,923) | ||||||||
| Balance at Jun. 30, 2024 | $ 2,760 | 1,234,385 | (1,795,254) | (558,109) | ||||||
| Balance, shares at Jun. 30, 2024 | 27,601,767 | |||||||||
| Net (loss) gain for the period | (216,269) | (216,269) | ||||||||
| Balance at Sep. 30, 2024 | $ 2,760 | 1,234,385 | (2,011,523) | (774,378) | ||||||
| Balance, shares at Sep. 30, 2024 | 27,601,767 | |||||||||
| Net (loss) gain for the period | (765,710) | (765,710) | ||||||||
| Balance at Dec. 31, 2024 | $ 22,000 | $ 2,760 | $ 32 | 1,215,113 | 1,234,385 | (2,777,233) | (2,777,233) | (1,540,088) | (1,540,088) | |
| Balance, shares at Dec. 31, 2024 | 440,000,000 | 27,601,767 | 322,059 | |||||||
| Issuance of shares under working capital loans and non redemption agreements | $ 554 | (554) | ||||||||
| Issuance of shares under working capital loans and non redemption agreements, shares | 5,536,946 | |||||||||
| Net (loss) gain for the period | $ 0 | 0 | (15,941,328) | (15,941,328) | ||||||
| Conversion of warrants | $ 574 | (574) | ||||||||
| Conversion of warrants, shares | 5,735,717 | |||||||||
| Issuance of shares in Reverse Acquisition | $ 726 | (4,603,302) | (4,602,576) | |||||||
| Issuance of shares in Reverse Acquisition, shares | 7,257,513 | |||||||||
| Issuance of commitment fee shares under ELOC agreement | $ 110 | (110) | ||||||||
| Issuance of commitment fee shares under ELOC agreement, shares | 1,106,527 | |||||||||
| Stock based compensation | $ 166 | 14,131,084 | 14,131,250 | |||||||
| Stock based compensation, shares | 1,662,500 | |||||||||
| Balance at Mar. 31, 2025 | $ 4,890 | 10,760,929 | (18,718,561) | (7,952,742) | ||||||
| Balance, shares at Mar. 31, 2025 | 48,900,970 | |||||||||
| Balance at Dec. 31, 2024 | $ 22,000 | $ 2,760 | $ 32 | $ 1,215,113 | 1,234,385 | $ (2,777,233) | (2,777,233) | $ (1,540,088) | (1,540,088) | |
| Balance, shares at Dec. 31, 2024 | 440,000,000 | 27,601,767 | 322,059 | |||||||
| Net (loss) gain for the period | (19,773,114) | |||||||||
| Balance at Sep. 30, 2025 | $ 4,953 | 11,078,116 | (22,550,347) | (11,467,278) | ||||||
| Balance, shares at Sep. 30, 2025 | 49,525,970 | |||||||||
| Balance at Mar. 31, 2025 | $ 4,890 | 10,760,929 | (18,718,561) | (7,952,742) | ||||||
| Balance, shares at Mar. 31, 2025 | 48,900,970 | |||||||||
| Net (loss) gain for the period | (1,981,293) | (1,981,293) | ||||||||
| Shares issued pursuant to settlement agreement | $ 63 | 317,187 | 317,250 | |||||||
| Shares issued pursuant to settlement agreement, shares | 625,000 | |||||||||
| Balance at Jun. 30, 2025 | $ 4,953 | 11,078,116 | (20,699,854) | (9,616,785) | ||||||
| Balance, shares at Jun. 30, 2025 | 49,525,970 | |||||||||
| Net (loss) gain for the period | (1,850,493) | (1,850,493) | ||||||||
| Balance at Sep. 30, 2025 | $ 4,953 | $ 11,078,116 | $ (22,550,347) | $ (11,467,278) | ||||||
| Balance, shares at Sep. 30, 2025 | 49,525,970 |